Dendreon (DNDN) Said PROVENGE Significantly Prolongs Survival for Men With Prostate Cancer
More News related to DNDN
- Dendreon Corp. (DNDN) Receives U.S. FDA Complete Response for PROVENGE CRPC Treatment
- Dendreon Receives FDA Acknowledgement of Complete Response
- Leerink Says Takeaway From Dendreon's (DNDN) Q3 Report is the Busy Preparations for Provenge
- Dendreon (DNDN) Reports Q3 Loss of $0.40, Misses by 19c
- Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
Dendreon Corporation (Nasdaq: DNDN) announced that its pivotal Phase 3 IMPACT study of PROVENGE in men with advanced prostate cancer met its primary endpoint of significantly improving overall survival compared to placebo.
The intent-to-treat analysis demonstrated that:
- PROVENGE extended median survival by 4.1 months compared to placebo (25.8 months versus 21.7 months);
- PROVENGE improved 3-year survival by 38% compared to placebo (31.7% versus 23.0%);
- The IMPACT study achieved a p-value of 0.032, successfully exceeding the pre-specified level of statistical significance defined by the study's design (p-value less than 0.043), and PROVENGE reduced the risk of death by 22.5% compared to placebo (HR=0.775); and
- PROVENGE exhibited a favorable safety profile consistent with prior trials.
Shares of DNDN plunged 45% ahead of the data.
Related Categories
FDAHot List
Stocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
